Transparency and the New Medical Device Reporting Rules
What to Do Now That ASR is Really Over

Friday, Oct. 4, 2019 • 1:30 p.m. - 3:00 p.m. EDT


Do you have a handle on the changes you may have to make to your MDR
program as a result of the Voluntary Malfunction Summary Reporting (VMSR) program?

And do you know how the FDA’s National Evaluation System for Health Technology (NEST) will impact you?

If you’re at all unsure, this webinar will deliver exactly what you need to ensure your organization’s MDR program is keeping pace with the changes brought by VMSR and NEST.

Two authorities from BioTeknica, Inc. — Julie Larsen, Principal Consultant and Director of Inspection Readiness Services and Lenita Sims-Spears, Esq., Senior QARA Consultant — will explain the implications for your organization and what to do to ensure you remain compliant.

Webinar Takeaways:

  • The real-world impact new medical device reporting programs will have following the formal end to the ASR program.
  • How the FDA is transitioning to the VMSR program.
  • Which devices and device malfunctions are eligible, or not, for summary reporting in VSMR.
  • Which events still require individual malfunction reports.
  • How to request summary reporting in VMSR.
  • The critical components of FDA’s NEST initiative — including how the agency will deploy real-world data to rapidly identify and address safety signals for devices on the market.
  • How the FDA will monitor medical device performance through NEST.

This webinar is the best way to understand the reporting process updates you may need to make so you can keep pace with VMSR and NEST. Join us by registering today.

Who Will Benefit

  • Quality Professionals (Managers, Directors)
  • Regulatory Professionals (Managers, Directors)
  • Individuals Responsible for MDR Reporting
  • Compliance Professionals

Webinar plus USB Audio Recording/Transcript
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus USB Audio Recording/Transcript
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

USB Audio Recording/Transcript
Learn more

$287

add to cart

 

Meet Your Presenters

Julie Larsen

Principal Consultant and Director of Inspection Readiness Services
BioTeknica, Inc.

Julie Larsen is a Principal Consultant and Director of Inspection Readiness Services at BioTeknica, Inc., a quality and regulatory compliance and engineering consulting firm in Coral Gables, Florida. She is a Certified Quality Manager (CQM), a Medical Technologist (MTASCP) and has more than 25 years’ experience in quality assurance and compliance in the medical device and pharmaceutical industries. Ms. Larsen has extensive experience in quality systems remediation for compliance improvement and constructing responses and corrective action plans for Consent Decree, Warning Letter and Form 483 responses as well as development of quality systems. Prior to BioTeknica, she held senior management positions including Senior Director, Compliance & Auditing and Director, Quality Commercial Operations at Abbott Diagnostics; Director, Quality for Abbott Hematology; Compliance Auditor, Abbott Corporate Regulatory & Quality Science; and GMP Compliance Officer, Abbott Pharmaceutical Products.

Lenita Sims-Spears, Esq.

Senior QARA Consultant
BioTeknica, Inc.

Lenita Sims-Spears, Esq. has been a Senior QARA Consultant with BioTeknica, Inc. for the past five years. She has 30 years’ experience in the medical device and pharmaceutical industry and has held roles of increasing responsibility for leading medical device companies worldwide, including Senior Director, Senior Manager and Program Lead. She is certified as a Lead Auditor and maintains her affiliations with ASQ, RAPS and FDLI. Ms. Sims-Spears is also a licensed attorney in Illinois and an adjunct professor at the John Marshall Law School in Chicago.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone (703) 538-7600 | Fax (703) 538-7676 | Toll free (888) 838-5578 | Email customerservice@fdanews.com

© 2019 FDAnews